- Home
- CBRE vs TOVX Comparison
CBRE vs TOVX Comparison
Compare CBRE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBRE | TOVX |
|---|---|---|
| Founded | 1906 | 2001 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5B | 14.7M |
| IPO Year | 2001 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CBRE | TOVX |
|---|---|---|
| Price | $130.93 | $0.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $177.86 | $1.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.61 | ★ 89.07 |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $40,550,000,000.00 | N/A |
| Revenue This Year | $14.31 | N/A |
| Revenue Next Year | $9.06 | N/A |
| P/E Ratio | $122.26 | ★ N/A |
| Revenue Growth | ★ 13.37 | N/A |
| 52 Week Low | $121.69 | $0.16 |
| 52 Week High | $174.27 | $0.86 |
Technical Indicators
Market Signals| Indicator | CBRE | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 36.63 |
| Support Level | $127.04 | $0.18 |
| Resistance Level | $138.73 | $0.27 |
| Average True Range (ATR) | 3.77 | 0.03 |
| MACD | 0.25 | -0.01 |
| Stochastic Oscillator | 79.47 | 4.77 |
Price Performance
Historical ComparisonAbout CBRE CBRE Group Inc
CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm managed over $155 billion (at year-end 2025) for clients across diverse public and private real estate strategies.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.